0LC7 Stock Overview
A biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Syros Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$8.10 |
| 52 Week Low | US$0.18 |
| Beta | 1.59 |
| 11 Month Change | -87.84% |
| 3 Month Change | -84.61% |
| 1 Year Change | -91.17% |
| 33 Year Change | -99.32% |
| 5 Year Change | n/a |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0LC7 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -10.9% | 1.5% | 1.7% |
| 1Y | -91.2% | -16.3% | 8.4% |
Return vs Industry: 0LC7 underperformed the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0LC7 underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| 0LC7 volatility | |
|---|---|
| 0LC7 Average Weekly Movement | 34.8% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0LC7's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0LC7's weekly volatility has increased from 26% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 68 | Conley Chee | www.syros.com |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. Fundamentals Summary
| 0LC7 fundamental statistics | |
|---|---|
| Market cap | US$6.73m |
| Earnings (TTM) | -US$97.81m |
| Revenue (TTM) | US$386.00k |
17.4x
P/S Ratio-0.1x
P/E RatioIs 0LC7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0LC7 income statement (TTM) | |
|---|---|
| Revenue | US$386.00k |
| Cost of Revenue | US$88.64m |
| Gross Profit | -US$88.25m |
| Other Expenses | US$9.56m |
| Earnings | -US$97.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.65 |
| Gross Margin | -22,862.95% |
| Net Profit Margin | -25,340.67% |
| Debt/Equity Ratio | -369.3% |
How did 0LC7 perform over the long term?
See historical performance and comparison